Serum Fetuin-A and COMP Levels in Knee Osteoarthritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAntalya Training and Research Hospital
About this trial
The purpose of this study is to investigate the relationship between the clinical and radiographic severity of knee osteoarthritis (OA) and the serum levels of specific biomarkers, namely Fetuin-A and Cartilage Oligomeric Matrix Protein (COMP). Osteoarthritis is a degenerative joint disease characterized by cartilage breakdown and low-grade inflammation. Investigating these biomarkers may help healthcare providers better understand the disease pathology, potentially leading to earlier diagnosis and improved tracking of disease progression. The study will compare two distinct groups: a patient group consisting of 120 individuals diagnosed with Grade 2-4 knee osteoarthritis, and a control group of 60 age- and sex-matched healthy volunteers with no history of joint disorders. Participants will undergo radiographic evaluations using the Kellgren-Lawrence classification system, alongside clinical and functional assessments, including pain severity scales, mobility metrics, and functional questionnaires. Fasting blood samples will be collected from all participants to measure serum Fetuin-A and COMP levels via laboratory analysis, and the Systemic Inflammation Response Index (SIRI) will be calculated. The collected data will be statistically analyzed to determine if biomarker levels significantly correlate with the severity of knee joint degeneration and functional impairment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Secondary post-traumatic knee osteoarthritis, history of major knee injury or joint infection. Signs of acute joint inflammation (swelling, heat increase, erythema). History of knee surgery (open or arthroscopic). Systemic inflammatory or autoimmune diseases. History of malignancy. Advanced renal or hepatic disease. Diagnosis of Diabetes Mellitus. Current use of systemic corticosteroids. Symptomatic osteoarthritis in other major joints (hip, hand, ankle, spine). Active systemic infection (fever ≥ 38, cough, diarrhea, dysuria, leukocytosis, or elevated CRP).
Trial population
The study population consisted of two main groups: a patient group and a healthy control group. The patient group included individuals who presented to the Physical Medicine and Rehabilitation Outpatient Clinics of SBÜ Antalya Training and Research Hospital and were diagnosed with primary knee osteoarthritis (Stage 2-4 according to the Kellgren-Lawrence classification system). The control group consisted of healthy volunteers of similar age and gender who did not have a known joint disorder, a history of knee pain, or a systemic inflammatory disease. All participants were selected using a single-center, hospital-based convenience sampling method during the specified study period.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
180 Participants
are grouped into 2 trial groupsGroup A: Knee Osteoarthritis Group
Group B: Healthy Control Group
Trial outcomes
Primary outcomes
1
Serum Fetuin-A Levels
Measurement of serum Fetuin-A concentration using a human-specific ELISA kit to evaluate its relationship with radiographic and clinical severity.
Time frame
Baseline (At the time of enrollment / single time point measurement)Secondary outcomes
1
Serum COMP (Cartilage Oligomeric Matrix Protein) Levels
Time frame
Baseline2
Radiographic Severity via Kellgren-Lawrence (K-L) Classification
Time frame
Baseline3
Clinical Severity and Functional Status via WOMAC Index
Time frame
Baseline4
Systemic Inflammation Response Index (SIRI)
(Neutrophil x Monocyte) / Lymphocyte
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Antalya Training and Research Hospital
Lead sponsor
Saglik Bilimleri Universitesi
Collaborator
Source ClinicalTrials.gov